same period of last year mainly due to lower aluminium prices.However, when comparing with previous quarter,it was increased 10.5% 2. Cost of sales was 431.57 million Baht or 107.58% of sales which

Analysis for the three-month period ended 31 March 2018 To : Director and the President The Stock Exchange of Thailand Summary of the Company’s Financial Position and Operating Result for the three-month

percent, in which the gross profit margin of the Company has decreased when compared to the same period of last year due to decreasing of The Company’s sales and services revenue but some of manufacturing

same period of last year and an increase of 24.9% over the last quarter . Such increase was mainly due to the increase in aluminium price and the expansion of sales volume from exporting to overseas

/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

Myanmar. Profit for the period L&E’s consolidated profit for the period of Q2/2018 was posted at Baht 24.7 million, up 194% or Baht 16.3 million from a year earlier, which can be summarized as follows: 1

earned premium moreover increased from 58.46% in the same period last year to 60.18% this year because of the fact that the average amount of claim expenses over accident related to voluntary motor

the same period of last year and an increase of 1.71% over the last quarter . Such increase was mainly due to the increase in aluminium price and the expansion of sales volume from exporting to overseas

and Valuation criteria of the transaction. 5.1) The transaction that the company made with the connected persons and their close relatives during period 6 months, the detail are as follows. 5.1.1) The

of L&E market share in Malaysia, Vietnam and Cambodia. Profit for the period L&E’s consolidated profit for the period of Q3/2018 was posted at Baht 35.1 million, up 36% or Baht 9.2 million from a year